Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

Previously untreated sALCL or other
CD30-expressing PTCLs ∨
Select
Lymphoma
Type
Previously untreated Stage III/IV cHLPediatric previously untreated high-risk cHLcHL post-auto-HSCT consolidationRelapsed cHLR/R LBCL after ≥2 prior lines of systemic therapyPreviously untreated sALCL or other CD30-expressing PTCLRelapsed pcALCL or CD30-expressing MFRelapsed sALCLLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EfficacySafetyDosageVideo LibraryMOA & Resources ∨MOA &
Resources
Patient ManagementMOA and CD30 TestingResourcesPatient Assistance
Prescribing InformationPatient InformationIndicationsLoadingPatient Site
SafetyADCETRIS+CHP has a comparable safety profile vs CHOP in CD30-expressing PTCL subtypesAdverse reactions reported in ≥10% of ECHELON-2 patients treated with A+CHP1Fatal adverse reactions occurred in 3% of patients in the A+CHP arm and in 4% of patients in the CHOP arms, most often from infection. Serious adverse reactions were reported in 38% of ADCETRIS + CHP-treated patients and 35% of CHOP-treated patients. Serious adverse reactions occurring in >2% of ADCETRIS + CHP-treated patients included febrile neutropenia (14%), pneumonia (5%), pyrexia (4%), and sepsis (3%).

In recipients of ADCETRIS + CHP, adverse reactions led to dose delays of ADCETRIS in 25% of patients, dose reduction in 9% (most often for peripheral neuropathy), and discontinuation of ADCETRIS with or without the other components in 7% (most often from peripheral neuropathy and infection).
Derived from laboratory values and adverse reaction data. Laboratory values were obtained at the start of each cycle and end of treatment. The table includes a combination of grouped and ungrouped terms. Events were graded using the NCI CTCAE Version 4.03.In ECHELON-2, most PN with A+CHP completely resolved or improved at last follow-up

The follow-up analysis of PN at 5 years was not prespecified in the protocol, is descriptive in nature, and offers supportive, but not conclusive, clinical information only. This analysis was not statistically powered to determine differences between treatment arms.

PN incidence and resolution during study and at last follow-up1–3

Similar incidence of PN was observed between treatment arms.

  • During the study, 52% (117/223) of patients in the ADCETRIS+CHP arm reported PN (34% Grade 1, 15% Grade 2, 3% Grade 3, <1% Grade 4)1,3
  • During the study, 55% (124/226) of patients in the CHOP arm reported PN
  • At 5 years, 19% (42/226) of patients in the CHOP arm had residual PN
79% due to rounding.View dose modifications for PN
  • Recommended starting dose: 1.8 mg/kg up to a maximum of 180 mg‡ in combination with CHP every 3 weeks for 6 to 8 doses1
Scroll left to view table
Adverse reactionSeverityDose modifications for PN
Sensory PNGrade 2
  • Continue treatment at same dose
Grade 3
  • Reduce dose to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks
Grade 4
  • Discontinue dosing
Motor PNGrade 2
  • Reduce dose to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks
Grade 3
  • Discontinue dosing
Grade 4
  • Discontinue dosing

Please see all additional dosing modifications

Peer perspective on long-term safety“We‘ll be looking at some recommendations to help you to manage adult patients with ADCETRIS+CHP in clinical practice.”Dr Francine Foss, hematologist-oncologist

Dr Francine Foss is presenting this program on behalf of Pfizer and is contracted with Pfizer for this service.

Help support your patients throughout their ADCETRIS treatment See Patient Management Strategies Loading < Back Efficacy Loading
Up next >
Dosage Loading
A+CHP = ADCETRIS + cyclophosphamide, doxorubicin, and prednisone; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone; CTCAE = common terminology criteria for adverse events; G-CFS = granulocyte colony-stimulating factor; NCI = National Cancer Institute; PTCL = peripheral T-cell lymphoma; sALCL = systemic anaplastic large cell lymphoma.References:ADCETRIS Prescribing Information. Bothell, WA: Seagen Inc. Horwitz S, O’Connor OA, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma. Virtual presentation at: 62nd Annual Meeting of the American Society of Hematology; December 5-8, 2020. Horwitz S, O’Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288-298.
Available on this page:

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-A1T-USA-1084
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
Indications

ADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL

  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.

Previously untreated high risk cHL

  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

cHL post-auto-HSCT consolidation

  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.

Relapsed cHL

  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

Previously untreated sALCL or other CD30-expressing PTCL

  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Relapsed sALCL

  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.

Relapsed pcALCL or CD30-expressing MF

  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.

Relapsed and Refractory Large B-Cell Lymphoma (LBCL)

  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.

Important Safety Information

BOXED WARNING

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.

CONTRAINDICATION

Contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).

WARNINGS AND PRECAUTIONS
Peripheral neuropathy (PN):
ADCETRIS causes PN that is predominantly sensory. Cases of motor PN have also been reported. ADCETRIS-induced PN is cumulative. Monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Patients experiencing new or worsening PN may require a delay, change in dose, or discontinuation of ADCETRIS.

Anaphylaxis and infusion reactions: Infusion-related reactions (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an IRR occurs, interrupt the infusion and institute appropriate medical management. If anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid.

Hematologic toxicities: Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (≥1  week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS.

Administer G-CSF primary prophylaxis beginning with Cycle 1 for adult  patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III/IV cHL or previously untreated PTCL or relapsed or refractory LBCL and pediatric patients who receive ADCETRIS in combination with chemotherapy for previously untreated high risk cHL.

Monitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays,  reductions, discontinuation, or G-CSF prophylaxis with subsequent doses.

Serious infections and opportunistic infections: Infections such as pneumonia, bacteremia, and sepsis or septic shock (including  fatal outcomes) have been reported in ADCETRIS-treated patients. Closely monitor patients during treatment for infections.

Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden may be at increased risk. Monitor closely and take appropriate measures.

Increased toxicity in the presence of severe renal impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment. Avoid use in patients with severe renal impairment.

Increased toxicity in the presence of moderate or severe hepatic impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment. Avoid use in patients with moderate or severe hepatic impairment.

Hepatotoxicity: Fatal and serious cases have occurred in ADCETRIS-treated patients. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first ADCETRIS dose or rechallenge. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin. Patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of ADCETRIS.

PML: Fatal cases of JC virus infection resulting in PML have been reported in ADCETRIS-treated patients. First onset of symptoms occurred at various times from initiation of ADCETRIS, with some cases occurring within 3 months of initial exposure. In addition to ADCETRIS therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider PML diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed.

Pulmonary toxicity: Fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. Monitor patients for signs and symptoms, including cough and  dyspnea. In the event of new or worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation and until symptomatic improvement.

Serious dermatologic reactions: Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and administer appropriate medical therapy.

Gastrointestinal (GI) complications: Fatal and serious cases of acute pancreatitis have been reported. Other fatal and serious GI complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. In the event of new or worsening GI symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately.

Hyperglycemia: Serious cases, such as new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, and ketoacidosis (including fatal outcomes) have been reported with ADCETRIS. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Monitor serum glucose and if hyperglycemia develops, administer anti-hyperglycemic medications as clinically indicated.

Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patients with female partners of reproductive potential to use effective contraception during ADCETRIS  treatment and for 4 months after the last dose of ADCETRIS.

ADVERSE REACTIONS
The most common adverse reactions (≥20%) in adult patients are  peripheral neuropathy, nausea, fatigue, musculoskeletal pain, constipation, diarrhea, vomiting, pyrexia, upper respiratory tract infection, mucositis, abdominal pain, and rash. The most common laboratory abnormalities (≥20%) in adult patients are decreased  neutrophils, increased creatinine, decreased hemoglobin, decreased lymphocytes, increased glucose, increased ALT, and increased AST. 

The most common Grade ≥3 adverse reactions (≥5%) in combination with AVEPC in pediatric patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection.

DRUG INTERACTIONS
Concomitant use of strong CYP3A4 inhibitors has the potential to affect  the exposure to monomethyl auristatin E (MMAE). Closely monitor adverse reactions.

USE IN SPECIAL POPULATIONS
Lactation: Breastfeeding is not recommended during ADCETRIS treatment.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.IndicationsADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL
  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Previously untreated high risk cHL
  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
cHL post-auto-HSCT consolidation
  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
Relapsed cHL
  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
Previously untreated sALCL or other CD30-expressing PTCL
  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Relapsed sALCL
  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.
Relapsed pcALCL or CD30-expressing MF
  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
Relapsed and Refractory Large B-Cell Lymphoma (LBCL)
  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.